open access

Vol 63, No 1 (2013)
Research paper (original)
Published online: 2013-03-08
Get Citation

Home parenteral nutrition (HPN) in incurable cancer patients: patients’ qualification criteria and treatment outcome

Stanisław Kłęk, Magda Piechowicz, Piotr Szybiński, Kinga Szczepanek, Magdalena Piętka, Piotr Wójcik, Agata Zoubek-Wójcik
Nowotwory. Journal of Oncology 2013;63(1):16-20.

open access

Vol 63, No 1 (2013)
Original article
Published online: 2013-03-08

Abstract

Aim. Parenteral nutrition (PN) represents a recognized therapeutic modality for intestinal failure patients, independently
of its etiology. Home parenteral nutrition (HPN) has, however, become controversial in oncological patients,
and creation of widely accepted indications for this treatment has become difficult. The aim of the study was to
assess treatment outcome in cancer HPN patients as well as to propose recommendations for this kind of treatment
in advanced cancer patients.


Material and methods. 69 patients (42 F, 27 M, mean age 58.1 y.) treated between January 2009 and June 2012 were
analyzed. The study group was formed of gastric, pancreatic, colon, esophagus, gall bladder, ovarian and uterus cancer
patients. The time of treatment and quality of life of the patients were analyzed.

Results. The mean overall survival time reached 99.8 days but varied among tumour groups. It was longer in ovarian and uterine cancer than in any other neoplasm (231.8 vs. 99.8 days, p < 0.05). The quality of life was also higher in the ovarian and uterine cancer group (7.8 vs. 4.3 points, p < 0.05) , while it was significantly lower in the others.

Conclusions. Home parenteral nutrition should be considered as a therapeutic option in every patient with advanced ovarian and uterine cancer. In other advanced cancer patients its use should be carefully considered as its value is not so convincing.

Abstract

Aim. Parenteral nutrition (PN) represents a recognized therapeutic modality for intestinal failure patients, independently
of its etiology. Home parenteral nutrition (HPN) has, however, become controversial in oncological patients,
and creation of widely accepted indications for this treatment has become difficult. The aim of the study was to
assess treatment outcome in cancer HPN patients as well as to propose recommendations for this kind of treatment
in advanced cancer patients.


Material and methods. 69 patients (42 F, 27 M, mean age 58.1 y.) treated between January 2009 and June 2012 were
analyzed. The study group was formed of gastric, pancreatic, colon, esophagus, gall bladder, ovarian and uterus cancer
patients. The time of treatment and quality of life of the patients were analyzed.

Results. The mean overall survival time reached 99.8 days but varied among tumour groups. It was longer in ovarian and uterine cancer than in any other neoplasm (231.8 vs. 99.8 days, p < 0.05). The quality of life was also higher in the ovarian and uterine cancer group (7.8 vs. 4.3 points, p < 0.05) , while it was significantly lower in the others.

Conclusions. Home parenteral nutrition should be considered as a therapeutic option in every patient with advanced ovarian and uterine cancer. In other advanced cancer patients its use should be carefully considered as its value is not so convincing.

Get Citation
About this article
Title

Home parenteral nutrition (HPN) in incurable cancer patients: patients’ qualification criteria and treatment outcome

Journal

Nowotwory. Journal of Oncology

Issue

Vol 63, No 1 (2013)

Article type

Research paper (original)

Pages

16-20

Published online

2013-03-08

Bibliographic record

Nowotwory. Journal of Oncology 2013;63(1):16-20.

Authors

Stanisław Kłęk
Magda Piechowicz
Piotr Szybiński
Kinga Szczepanek
Magdalena Piętka
Piotr Wójcik
Agata Zoubek-Wójcik

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media sp. z o.o. VM Group sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl